Cybin Announces Phase 2 Cohort 5 Dosing Completion Of CYB003 In Major Depressive Disorder
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. has announced the completion of Phase 2 Cohort 5 dosing of CYB003 in Major Depressive Disorder. This marks a significant milestone in the development of the drug.
July 24, 2023 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has completed a significant phase in the development of CYB003. This could potentially lead to positive investor sentiment.
The completion of Phase 2 Cohort 5 dosing of CYB003 is a significant milestone in the drug's development. This could potentially lead to positive investor sentiment and an increase in Cybin Inc.'s stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100